SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Blennow Kaj 1958 ) "

Sökning: WFRF:(Blennow Kaj 1958 )

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Anckarsäter, Rolf, 1956, et al. (författare)
  • Cerebrospinal fluid protein reactions during non-neurological surgery.
  • 2007
  • Ingår i: Acta neurologica Scandinavica. - : Wiley-Blackwell. - 0001-6314 .- 1600-0404. ; 115:4, s. 254-9
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVE: To study changes in cerebrospinal fluid (CSF) protein markers of blood-CSF barrier integrity and immunological reactions during surgical stress. SUBJECTS AND METHODS: Thirty-five patients without neurological or psychiatric disorders undergoing knee replacements had CSF and serum samples drawn from spinal and arterial catheters before, 3 h after and the morning after surgery. RESULTS: Serum albumin decreased during surgery and CSF albumin decreased during and after surgery, and, as a consequence, the CSF/serum albumin ratio decreased significantly during the study period, especially after the intervention. In contrast, CSF concentrations of beta-2-microglobuline (beta2M) increased significantly during surgery and remained high. The CSF general marker beta-trace protein (betaTP) remained unchanged. CONCLUSIONS: Central nervous system protein reactions to a non-neurological surgical intervention include sharply decreased permeability of albumin into the CSF and signs of intrathecal inflammatory activity.
  •  
2.
  • Hakansson, I., et al. (författare)
  • Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis
  • 2017
  • Ingår i: European Journal of Neurology. - : WILEY. - 1351-5101 .- 1468-1331. ; 24:5, s. 703-712
  • Tidskriftsartikel (refereegranskat)abstract
    • Background and purpose: Improved biomarkers are needed to facilitate clinical decision-making and as surrogate endpoints in clinical trials in multiple sclerosis (MS). We assessed whether neurodegenerative and neuroinflammatory markers in cerebrospinal fluid (CSF) at initial sampling could predict disease activity during 2 years of follow-up in patients with clinically isolated syndrome (CIS) and relapsing-remitting MS. Methods: Using multiplex bead array and enzyme-linked immunosorbent assay, CXCL1, CXCL8, CXCL10, CXCL13, CCL20, CCL22, neurofilament light chain (NFL), neurofilament heavy chain, glial fibrillary acidic protein, chitinase-3-like-1, matrix metalloproteinase-9 and osteopontin were analysed in CSF from 41 patients with CIS or relapsing-remitting MS and 22 healthy controls. Disease activity (relapses, magnetic resonance imaging activity or disability worsening) in patients was recorded during 2 years of follow-up in this prospective longitudinal cohort study. Results: In a logistic regression analysis model, NFL in CSF at baseline emerged as the best predictive marker, correctly classifying 93% of patients who showed evidence of disease activity during 2 years of follow-up and 67% of patients who did not, with an overall proportion of 85% (33 of 39 patients) correctly classified. Combining NFL with either neurofilament heavy chain or osteopontin resulted in 87% overall correctly classified patients, whereas combining NFL with a chemokine did not improve results. Conclusions: This study demonstrates the potential prognostic value of NFL in baseline CSF in CIS and relapsing-remitting MS and supports its use as a predictive biomarker of disease activity.
  •  
3.
  •  
4.
  • Mattsson, Niklas, 1979, et al. (författare)
  • Age and diagnostic performance of Alzheimer disease CSF biomarkers.
  • 2012
  • Ingår i: Neurology. - : American Academy of Neurology (AAN). - 1526-632X .- 0028-3878. ; 78:7, s. 468-76
  • Tidskriftsartikel (refereegranskat)abstract
    • Core CSF changes in Alzheimer disease (AD) are decreased amyloid β(1-42), increased total tau, and increased phospho-tau, probably indicating amyloid plaque accumulation, axonal degeneration, and tangle pathology, respectively. These biomarkers identify AD already at the predementia stage, but their diagnostic performance might be affected by age-dependent increase of AD-type brain pathology in cognitively unaffected elderly.
  •  
5.
  • Mattsson, Niklas, 1979, et al. (författare)
  • Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis.
  • 2009
  • Ingår i: Multiple sclerosis (Houndmills, Basingstoke, England). - : SAGE Publications. - 1352-4585. ; 15:4, s. 448-454
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Cell and animal experiments have shown that beta-site APP-cleaving enzyme 1 (BACE1) may be involved in myelination. OBJECTIVE: Here, we assess the association of cerebrospinal fluid (CSF) BACE1 activity with multiple sclerosis (MS). METHODS: BACE1 activity and levels of secreted amyloid precursor protein (APP) and amyloid-beta (Abeta) isoforms were analyzed in CSF from 100 patients with MS and 114 neurologically healthy controls. Patients with systemic lupus erythematosus (SLE), 26 with and 41 without cerebral engagement, were also included to enable comparisons with regards to another autoimmune disease. A subset of patients with MS and controls underwent a second lumbar puncture after 10 years. RESULTS: MS patients had lower CSF BACE1 activity than controls (P = 0.03) and patients with cerebral SLE (P < 0.001). Patients with cerebral SLE had higher BACE1 activity than any other group (P < 0.05 for all comparisons). BACE1 activity correlated with the different amyloid markers in all study groups. BACE1 activity decreased over 10 years in the MS group (P = 0.039) and correlated weakly with clinical disease severity scores in an inverse manner. CONCLUSIONS: These results suggest an involvement of BACE1 in the MS disease process.
  •  
6.
  • Nilselid, Anna-Maria, 1967, et al. (författare)
  • Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms
  • 2006
  • Ingår i: Neurochem Int.. - : Elsevier. ; 48:8, s. 718-728
  • Tidskriftsartikel (refereegranskat)abstract
    • Clusterin is suggested to be involved in the pathogenesis of Alzheimer's disease. Clusterin expression is increased in brain tissue in affected regions of Alzheimer patients, and intense clusterin staining is found in both senile plaques and in neuronal and glia cells. In contrast, the cerebrospinal fluid level of clusterin in Alzheimer patients has, thus far, been found unchanged. Clusterin is a glycosylated protein, and an alteration of its glycosylation in Alzheimer's disease might influence accurate quantification in cerebrospinal fluid through interference of antibody binding to the protein. Using enzymatic deglycosylation of clusterin isolated from cerebrospinal fluid, we found that the carbohydrates attached to clusterin were of the N-linked type and sialic acids. Based on this finding, cerebrospinal fluid samples from Alzheimer patients (n = 99) and controls (n = 39) were analysed. The samples were treated with peptide: N-glycanase F, cleaving off N-linked carbohydrates, and clusterin was quantified before and after deglycosylation using a new sandwich enzyme-linked immunosorbent assay. Clusterin was significantly increased in Alzheimer patients, in both native (7.17 ± 2.43 AU versus 5.73 ± 2.09 AU; p = 0.002), and deglycosylated samples (12.19 ± 5.00 AU versus 9.68 ± 4.38 AU; p = 0.004). Deglycosylation led to increased measured levels of clusterin by 70% (p < 0.001) in Alzheimer patients and 67% (p < 0.001) in controls. These findings indicate that glycosylation of proteins may interfere with their quantification. The results show that clusterin is significantly increased in cerebrospinal fluid from Alzheimer patients as a group, supporting that clusterin might be involved in the pathogenesis of Alzheimer's disease. However, the individual clusterin levels overlap between the two groups, and thus cerebrospinal fluid clusterin measurement is not suitable as a biochemical marker in the diagnosis of Alzheimer's disease.
  •  
7.
  • Parnetti, L, et al. (författare)
  • Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease.
  • 2011
  • Ingår i: Acta neurologica Scandinavica. - : Wiley-Blackwell. - 1600-0404. ; 124:2, s. 122-129
  • Tidskriftsartikel (refereegranskat)abstract
    • Objectives - To measure cerebrospinal fluid (CSF) activity of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) in patients with Alzheimer's disease (AD) participating in randomized clinical trials from three European centers, before and after long-term treatment with different AChE inhibitors (AChEIs). Materials and methods - Of the 144 patients included in the study, 104 were treated with donepezil, 15 with galantamine, 16 with rivastigmine, and nine with placebo. CSF AChE and BChE activities were measured at baseline and after 1- year treatment. Results - Donepezil and galantamine groups showed a significant increase in CSF AChE activity at follow-up, while no changes for BChE activity were observed; in donepezil group, a positive correlation between plasma concentration and AChE activity was documented. Conversely, in rivastigmine group, a decrease in CSF activity of both enzymes was observed. CSF AChE and BChE activities were not correlated with the clinical outcome in any group considered. CSF biomarkers did not show any change after treatment. Conclusions - AChEIs differently influence the activity of target enzymes in CSF independent of their pharmacodynamic effects.
  •  
8.
  • Rüetschi, Ulla, 1962, et al. (författare)
  • Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF.
  • 2005
  • Ingår i: Experimental neurology. - : Academic Press. - 0014-4886. ; 196:2, s. 273-81
  • Tidskriftsartikel (refereegranskat)abstract
    • This investigation describes the discovery of novel possible cerebrospinal fluid (CSF) biomarkers for frontotemporal dementia (FTD) using surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry (MS). Sixteen clinically diagnosed FTD patients and 12 non-demented controls were included in the study. CSF was collected and analyzed for protein expression by SELDI-TOF MS. The samples were analyzed on four different array surfaces using two different energy-absorbing molecules as matrices. In total each sample was subjected to eight different surface/matrix conditions. About 2000 protein peaks (mass/charge ratios) were detected. Forty-two peaks were differentially expressed in FTD (P < 0.01). After exclusion of peaks with low signal-to-noise ratio and/or poor resolution and peaks representing differentially charged proteins, 10 peaks remained, five of which were increased and five decreased in FTD cases compared to controls. Using partial least square discriminant analysis (PLS-DA), the combination of these biomarkers discriminated FTD from non-demented controls with a sensitivity of 94%, a specificity of 83% and an accuracy of 89%. Five of the peaks were purified further and identified by tandem MS as a fragment of neurosecretory protein VGF, transthyretin, S-cysteinylated transthyretin, truncated cystatin C and a fragment of chromogranin B. With use of these potential biomarkers, FTD can be distinguished from control subjects with high accuracy in this pilot study.
  •  
9.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
Typ av publikation
tidskriftsartikel (1040)
forskningsöversikt (60)
konferensbidrag (26)
bokkapitel (13)
bok (7)
samlingsverk (redaktörskap) (1)
visa fler...
annan publikation (1)
visa färre...
Typ av innehåll
refereegranskat (1088)
övrigt vetenskapligt (59)
populärvet., debatt m.m. (1)
Författare/redaktör
Blennow, Kaj, 1958 (1147)
Zetterberg, Henrik, ... (881)
Blennow, K (210)
Zetterberg, H (135)
Andreasson, Ulf, 196 ... (135)
Portelius, Erik, 197 ... (109)
visa fler...
Hansson, Oskar (99)
Wallin, Anders, 1950 (93)
Andreasen, N (80)
Mattsson, Niklas, 19 ... (79)
Andreasen, Niels (71)
Skoog, Ingmar, 1954 (65)
Hampel, Harald (57)
Minthon, Lennart (55)
Minthon, L (52)
Hansson, O. (50)
Brinkmalm, Gunnar (49)
Rosengren, Lars, 195 ... (43)
Hampel, H. (42)
Scheltens, P (41)
Höglund, Kina, 1976 (40)
Minthon, Lennart, 19 ... (39)
Brinkmalm-Westman, A ... (36)
Shaw, Leslie M (35)
Wallin, A (33)
Winblad, B (32)
Trojanowski, John Q (32)
Kern, Silke (31)
Scheltens, Philip (30)
Tsolaki, M (26)
Visser, PJ (26)
Parnetti, Lucilla (26)
Nordberg, A (25)
Olsson, Bob, 1969 (24)
Andreasson, U (24)
Parnetti, L (24)
Londos, Elisabet (23)
Lewczuk, Piotr (23)
Svensson, Johan, 196 ... (23)
Engelborghs, Sebasti ... (23)
Ashton, Nicholas J. (23)
Visser, Pieter Jelle (23)
Bjerke, Maria, 1977 (23)
Pannee, Josef, 1979 (22)
Soininen, H (22)
Teunissen, Charlotte ... (22)
Molinuevo, José Luis (22)
Johnson, Sterling C (22)
Vanmechelen, Eugeen (22)
Vanderstichele, Hugo (22)
visa färre...
Lärosäte
Göteborgs universitet (1143)
Lunds universitet (135)
Karolinska Institutet (123)
Uppsala universitet (27)
Chalmers tekniska högskola (24)
Linköpings universitet (20)
visa fler...
Umeå universitet (11)
Luleå tekniska universitet (8)
Örebro universitet (5)
Stockholms universitet (4)
Kungliga Tekniska Högskolan (2)
Jönköping University (2)
Linnéuniversitetet (2)
Högskolan i Skövde (1)
VTI - Statens väg- och transportforskningsinstitut (1)
visa färre...
Språk
Engelska (1124)
Svenska (22)
Odefinierat språk (2)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (1023)
Naturvetenskap (32)
Samhällsvetenskap (13)
Teknik (1)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy